Our hypothesis suggests that 5-ASA, via activation of PPAR-γ and TGF-β and inhibition of the NFκ-B pathway, could benefit DW patients by addressing inflammation, circulatory issues, impaired tissue regeneration, and neuropathy. This evidence concerns the gene NFKB1 and neuropathy.